Fernando Scudiero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/65285/publications.pdf

Version: 2024-02-01

50 papers 2,416 citations

304743 22 h-index 223800 46 g-index

50 all docs 50 docs citations

50 times ranked

2933 citing authors

#	Article	IF	CITATIONS
1	Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose–Response. Cardiovascular Drugs and Therapy, 2023, 37, 695-703.	2.6	7
2	Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes. Platelets, 2022, 33, 390-397.	2.3	3
3	Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients. Cardiovascular Drugs and Therapy, 2022, 36, 705-712.	2.6	15
4	Long-Term Prognostic Impact of Right Ventricular Dysfunction in Patients with COVID-19. Journal of Personalized Medicine, 2022, 12, 162.	2.5	4
5	Clinical Outcome of Hospitalized COVID-19 Patients with History of Atrial Fibrillation. Medicina (Lithuania), 2022, 58, 399.	2.0	2
6	Outcomes of Left Main Revascularization after Percutaneous Intervention or Bypass Surgery. Journal of Interventional Cardiology, 2022, 2022, 1-9.	1.2	4
7	Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thrombosis Research, 2021, 198, 34-39.	1.7	79
8	Pre-admission atrial fibrillation in COVID-19 patients: Prevalence and clinical impact. European Journal of Internal Medicine, 2021, 88, 133-135.	2.2	9
9	Preadmission Statin Therapy and Clinical Outcome in Hospitalized Patients With COVID-19: An Italian Multicenter Observational Study. Journal of Cardiovascular Pharmacology, 2021, 78, e94-e100.	1.9	11
10	Orodispersible Ticagrelor in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2021, 78, 292-294.	2.8	12
11	Clinical conditions and echocardiographic parameters associated with mortality in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13638.	3.4	26
12	Predictors of Recurrent Ischemic Events in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 159, 44-51.	1.6	14
13	Acute pulmonary embolism in COVID-19 patient: a case report of free-floating right heart thrombus successfully treated with fibrinolysis. European Heart Journal - Case Reports, 2021, 5, ytaa388.	0.6	6
14	Prognostic Implications of Right Ventricular Function and Pulmonary Pressures Assessed by Echocardiography in Hospitalized Patients with COVID-19. Journal of Personalized Medicine, 2021, 11, 1245.	2.5	7
15	Beneficial Effects of Listening to Classical Music in Patients With Heart Failure: A Randomized Controlled Trial. Journal of Cardiac Failure, 2020, 26, 541-549.	1.7	24
16	Platelet Reactivity in Hepatitis C Virus–Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. Journal of the American Heart Association, 2020, 9, e016441.	3.7	7
17	Clinical characteristics and prognosis of hospitalized COVIDâ€19 patients with incident sustained tachyarrhythmias: A multicenter observational study. European Journal of Clinical Investigation, 2020, 50, e13387.	3.4	54
18	The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 262-264.	3.0	20

#	Article	IF	CITATIONS
19	Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacological Research, 2020, 159, 104965.	7.1	97
20	Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemia: the right choice at the right time. Journal of Cardiovascular Medicine, 2020, 21, 535-537.	1.5	8
21	Relationship between CHA 2 DS 2 -VASc score, coronary artery disease severity, residual platelet reactivity and long-term clinical outcomes in patients with acute coronary syndrome. International Journal of Cardiology, 2018, 262, 9-13.	1.7	18
22	Risk Stratification Using the CHA ₂ DS ₂ â€VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network. Journal of the American Heart Association, 2017, 6, .	3.7	22
23	The long way to better PCI results in diabetic patients. International Journal of Cardiology, 2017, 245, 90-91.	1.7	0
24	TOTAL evidence for drug eluting stent efficacy and safety in STEMI patients. International Journal of Cardiology, 2017, 248, 124-125.	1.7	0
25	Clinical events beyond one year after an acute coronary syndrome: insights from the RECLOSE 2-ACS study. EuroIntervention, 2017, 12, 2018-2024.	3.2	13
26	Angiographic and Clinical Outcomes AfterÂEverolimus-Eluting Stenting for Unprotected Left Main Disease and HighÂAnatomic Coronary Complexity. JACC: Cardiovascular Interventions, 2016, 9, 1001-1007.	2.9	17
27	Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. International Journal of Cardiology, 2016, 221, 567-571.	1.7	41
28	Editor's Choice-Chest pain relief in patients with acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 277-281.	1.0	23
29	Diagnosis and Evaluation of Stent Thrombosis with Optical Coherence Tomography. Interventional Cardiology Clinics, 2015, 4, 295-307.	0.4	0
30	Ticagrelor Crushed Tablets Administration in STEMI Patients. Journal of the American College of Cardiology, 2015, 65, 511-512.	2.8	167
31	Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	164
32	Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. Journal of Thrombosis and Thrombolysis, 2015, 40, 76-82.	2.1	27
33	Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 555-560.	1.0	45
34	Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. American Heart Journal, 2014, 167, 909-914.	2.7	48
35	Switching from ticagrelor to prasugrel: A warning. International Journal of Cardiology, 2014, 176, 1089-1090.	1.7	2
36	Residual platelet reactivity and outcomes with 5mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2014, 176, 874-877.	1.7	8

#	Article	IF	CITATIONS
37	Revised clinical diagnostic criteria for Tako-tsubo syndrome: The Tako-tsubo Italian Network proposal. International Journal of Cardiology, 2014, 172, 282-283.	1.7	85
38	Reply. Journal of the American College of Cardiology, 2013, 62, 1637.	2.8	0
39	Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2013, 61, 1601-1606.	2.8	403
40	Tako-tsubo cardiomyopathy and coronary artery disease. Coronary Artery Disease, 2013, 24, 527-533.	0.7	56
41	Clinical and Angiographic Outcomes of Patients Treated With Everolimus-Eluting Stents or First-Generation Paclitaxel-Eluting Stents for Unprotected Left Main Disease. Journal of the American College of Cardiology, 2012, 60, 1217-1222.	2.8	40
42	Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel. American Journal of Cardiology, 2012, 109, 214-218.	1.6	66
43	Natural History of Tako-Tsubo Cardiomyopathy. Chest, 2011, 139, 887-892.	0.8	133
44	Anxiety trait in patients with stress-induced cardiomyopathy: a case–control study. Clinical Research in Cardiology, 2011, 100, 523-529.	3.3	49
45	High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI. JAMA - Journal of the American Medical Association, 2011, 306, 1215.	7.4	361
46	Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 796-802.	2.9	21
47	Left ventricular remodeling after primary percutaneous coronary intervention. American Heart Journal, 2010, 160, S11-S15.	2.7	13
48	Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis, 2010, 211, 255-259.	0.8	46
49	High Residual Platelet Reactivity After Clopidogrel Loading and Long-Term Clinical Outcome After Drug-Eluting Stenting for Unprotected Left Main Coronary Disease. Circulation, 2009, 120, 2214-2221.	1.6	114
50	Effectiveness of Primary Percutaneous Coronary Interventions for Stent Thrombosis. American Journal of Cardiology, 2009, 103, 913-916.	1.6	25